share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/09/26 13:37

Moomoo AI 已提取核心信息

Alterity Therapeutics has released its Corporate Governance Statement for the fiscal year ended June 30, 2024, outlining its commitment to maintaining high ethical standards and statutory compliance. The statement details the company's governance framework aligned with ASX Corporate Governance Council's Principles and Recommendations.The Board structure comprises 4 directors, all male, with extensive industry experience and professional qualifications. The company maintains two key committees: Audit and Remuneration, both chaired by independent directors. The workforce demonstrates gender diversity with 47% female representation, though all board positions are currently held by men.The statement highlights robust risk management processes, remuneration policies, and disclosure practices. Key features include regular board performance reviews, a comprehensive code of conduct, and policies on anti-bribery, whistleblowing, and continuous disclosure. The company emphasizes shareholder engagement through various communication channels and maintains transparency in financial reporting.
Alterity Therapeutics has released its Corporate Governance Statement for the fiscal year ended June 30, 2024, outlining its commitment to maintaining high ethical standards and statutory compliance. The statement details the company's governance framework aligned with ASX Corporate Governance Council's Principles and Recommendations.The Board structure comprises 4 directors, all male, with extensive industry experience and professional qualifications. The company maintains two key committees: Audit and Remuneration, both chaired by independent directors. The workforce demonstrates gender diversity with 47% female representation, though all board positions are currently held by men.The statement highlights robust risk management processes, remuneration policies, and disclosure practices. Key features include regular board performance reviews, a comprehensive code of conduct, and policies on anti-bribery, whistleblowing, and continuous disclosure. The company emphasizes shareholder engagement through various communication channels and maintains transparency in financial reporting.
Alterity Therapeutics发布了截至2024年6月30日的财年公司治理声明，概述了其维护高道德标准和法定合规的承诺。该声明详细说明了公司与ASX公司治理委员会原则与建议相一致的治理框架。董事会结构由4名男性董事组成，他们拥有丰富的行业经验和专业资格。公司设有两个关键委员会：审计委员会和薪酬委员会，均由独立董事担任主席。劳动力展示了性别多样性，女性占比47%，但目前所有董事会职位均由男性担任。该声明强调了健全的风险管理流程、薪酬政策和信息披露实践。主要特点包括定期董事会绩效评估、全面的行为准则以及关于反贿赂、吹哨和持续披露的政策。公司通过各种沟通渠道强调与股东的互动，并保持财务报告的透明度。
Alterity Therapeutics发布了截至2024年6月30日的财年公司治理声明，概述了其维护高道德标准和法定合规的承诺。该声明详细说明了公司与ASX公司治理委员会原则与建议相一致的治理框架。董事会结构由4名男性董事组成，他们拥有丰富的行业经验和专业资格。公司设有两个关键委员会：审计委员会和薪酬委员会，均由独立董事担任主席。劳动力展示了性别多样性，女性占比47%，但目前所有董事会职位均由男性担任。该声明强调了健全的风险管理流程、薪酬政策和信息披露实践。主要特点包括定期董事会绩效评估、全面的行为准则以及关于反贿赂、吹哨和持续披露的政策。公司通过各种沟通渠道强调与股东的互动，并保持财务报告的透明度。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Corcept医疗
    CORT
    -- 106.335
    bluebird bio
    BLUE
    -- 5.145
    ABVC BioPharma
    ABVC
    -- 1.0300
    NLS Pharmaceutics
    NLSP
    -- 1.4800
    Rein Therapeutics
    RNTX
    -- 1.920
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日